ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FNA Paragon 28 Inc

7.97
0.00 (0.00%)
Pre Market
Last Updated: 12:12:15
Delayed by 15 minutes
Share Name Share Symbol Market Type
Paragon 28 Inc NYSE:FNA NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.97 63 12:12:15

Paragon 28 to Present at the Canaccord Genuity 43rd Annual Growth Conference

28/07/2023 1:00pm

Business Wire


Paragon 28 (NYSE:FNA)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Paragon 28 Charts.

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time.

A live webcast, as well as the archived recording, will be available on the investor relations section of the Company’s website at ir.paragon28.com.

About Paragon 28, Inc.

Based in Englewood, Colo., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Investor Contact: Matt Brinckman Senior Vice President, Strategy and Investor Relations (720) 912-1332 mbrinckman@paragon28.com

1 Year Paragon 28 Chart

1 Year Paragon 28 Chart

1 Month Paragon 28 Chart

1 Month Paragon 28 Chart